drugset / Trial / NCT03659448

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

NCT03659448 ↗

Phase 3 Recruiting 300 enrolled Surgimab
RandomizedParallel-groupOpen-labelOther

Summary

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Timeline

Start
2019-06-17
Primary completion
2024-11
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator SGM-101 Monoclonal antibody — —

Indications